Meibomitis-Related keratoconjunctivitis: Implications and clinical significance of meibomian gland inflammation

Cornea

Volumn 31, Issue 11 SUPPL.1, 2012, Pages

  Suzuki, Tomo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

acne rosacea; female prevalence; keratoconjunctivitis; meibomitis; Propionibacterium acnes

Indexed keywords

ANTIINFECTIVE AGENT; CEFMENOXIME; CEPHALOSPORIN; CLARITHROMYCIN; LEUKOCYTE ANTIGEN;

ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; BACTERIUM DETECTION; CLINICAL FEATURE; CONFERENCE PAPER; CONJUNCTIVAL HYPEREMIA; DISEASE ASSOCIATION; EYE REDNESS; KERATOCONJUNCTIVITIS; MEIBOMIAN GLAND; MEIBOMIANITIS; MEIBOMITIS RELATED KERATOCONJUNCTIVITIS; OCULAR SURFACE DISEASE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; SWELLING; VASCULARIZATION;

AGE FACTORS; ANTI-BACTERIAL AGENTS; BLEPHARITIS; CEPHALOSPORINS; CLARITHROMYCIN; EYE INFECTIONS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KERATOCONJUNCTIVITIS; MEIBOMIAN GLANDS; PREVALENCE; PROPIONIBACTERIUM ACNES; SEX FACTORS;

EID: 84867344213     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31826a04dd     Document Type: Conference Paper

References (33)

1. Lemp MA, Nichols KK. Blepharitis in the United States 2009: A surveybased perspective on prevalence and treatment. Ocul Surf. 2009;7:S1-S14.
2. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;30:1922-1929.
3. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996;40:343-367.
4. Jester JV, Nicolaides N, Smith RE. Meibomian gland studies: Histologic and ultrastructural investigations. Invest Ophthalmol Vis Sci. 1981;20: 537-547.
5. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol. 1982;94:383-387.
6. Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc. 1980;51:243-251.
7. Foulks GN, Bron AJ. Meibomian gland dysfunction: A clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1: 107-126.
8. Duke-Elder W, MacFaul P. The ocular adnexa, Part 1: inflammations of the lid margins. In: Duke-Elder W, MacFaul P, eds. System of Ophthalmology. London, United Kingdom: H. Kimpron; 1974:205-250.
9. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: Report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52: 1930-1937.
10. Elschinig A. Conjunctivitis meibomiana. D Med W. 1908;34:1133.
11. Thygeson P, Kimura SJ. Chronic conjunctivitis. Trans Am Acad Ophthalmol Otolaryngol. 1963;67:494.
12. McCulley JP, Sciallis GF. Meibomian keratoconjunctivitis. Am J Ophthalmol. 1977;84:788-793.
13. Suzuki T, Yokoi N, Sano Y, et al. Clinical study of corneal epithelial damage related to meibomitis (Meibomitis-related keratopathy). Atarashii Ganka. 2000;17:412-427.
14. Suzuki T, Mitsuishi Y, Sano Y, et al. Phlyctenular keratitis associated with meibomitis in young patients. Am J Ophthalmol. 2005;140:77-82.
15. Suzuki T, Kinoshita S. Meibomitis-related keratoconjunctivitis in childhood and adolescence. Am J Ophthalmol. 2007;144:160-161; author reply 161.
16. Sorsby A. The aetiology and treatment of phlyctenular ophthalmia. Br J Ophthalmol. 1942;26:159-215.
17. Thygeson P. The etiology and treatment of phlyctenular keratoconjunctivitis. The Estelle L. Doheny Lecture. Am J Ophthalmol. 1951;34: 1217-1236.
18. Thygeson P. Complications of staphylococcic blepharitis. Am J Ophthalmol. 1969;68:446-449.
19. Smolin G, Okumoto M. Staphylococcal blepharitis. Arch Ophthalmol. 1977;95:812-816.
20. Zaidman GW, Brown SI. Orally administered tetracycline for phlyctenular keratoconjunctivitis. Am J Ophthalmol. 1981;92:178-182.
21. Culbertson WW, Huang AJ, Mandelbaum SH, et al. Effective treatment of phlyctenular keratoconjunctivitis with oral tetracycline. Ophthalmology. 1993;100:1358-1366.
22. Kligman AM. An overview of acne. J Invest Dermatol. 1974;62: 268-287.
23. Webster GF, Leyden JJ, Norman ME, et al. Complement activation in acne vulgaris: in vitro studies with Propionibacterium acnes and Propionibacterium granulosum. Infect Immun. 1978;22:523-529.
24. Webster GF, Leyden JJ. Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation. 1980;4:261-269.
25. Knop J, Riechmann R, Macher E. Modulation of suppressor mechanism in allergic contact dermatitis. IV. Selective inhibition of suppressor Tlymphocytes by serum obtained from Corynebacterium parvum treated mice. J Invest Dermatol. 1981;77:469-473.
26. Webster GF, Leyden JJ, Musson RA, et al. Susceptibility of Propionibacterium acnes to killing and degradation by human neutrophils and monocytes in vitro. Infect Immun. 1985;49:116-121.
27. Suzuki T, Sano Y, Sasaki O, et al. Ocular surface inflammation induced by Propionibacterium acnes. Cornea. 2002;21:812-817.
28. Abu el-Asrar AM, Van den Oord JJ, Geboes K, et al. Phenotypic characterization of inflammatory cells in phlyctenular eye disease. Doc Ophthalmol. 1988;70:353-362.
29. Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol. 2004;137:138-144.
30. Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: Long-term treatment with systemic antibiotics. Am J Ophthalmol. 2006;142:816-821.
31. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea. 2007;26:42-46.
32. Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol. 1986;31: 145-158.
33. Suzuki T, Sano Y, Yokoi N, et al. Clinical entity similarities between meibomitis-related keratoconjunctivitis and ocular rosacea. Invest Ophthalmol Vis Sci. 2011;52:ARVO E-Abstract 1504.